Biogen's Alzheimer's drug blocked in Japan
The Japanese health authorities won't approve Biogen's Aduhelm, a treatment for Alzheimer's disease, without first receiving additional data.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Alzheimer's drug Aduhelm, which is marketed in a collaboration between Biogen and Eisai, is facing many problems the latest of which is found in Japan.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP approves 13 new drugs
For subscribers
Biogen slashes price of controversial Alzheimer's drug
For subscribers
Biogen's Aduhelm rejected by EMA committee
For subscribers
